In addition, longitudinally monitoring PIK3CA mutation levels in ctDNA have been found to predict patient progression‐free survival (PFS) in ER+ metastatic BC patients (Gerratana et al., 2019), implying the great clinical values of using ctDNA for diagnosis and prognosis of BC. This evidence concerns the gene PIK3CA and breast cancer.